Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q4 2025 Earnings Presentation
28 slides from Heartbeam's earnings presentation, Mar 12, 2026
Slide 1: Total Heart Intelligence… Wherever You Are
Total Heart Intelligence… Wherever You Are FOURTH QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL MARCH 12, 2026 NASDAQ: BEAT
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and
Slide 3: Agenda
Agenda WHAT WE’LL COVER: ON THE CALL TODAY: HeartBeam’s Core Technology and Platform HeartBeam System: Limited Commercial Launch Heart Atack Detection ROB ENO TIM CRUICKSHANK BRYAN HUMBARGER Unveiling the 12-Lead ECG Patch AI Initiatives Financials Fourth Quarter 2025 Financial Results Conference Ca
Slide 4: A Cardiac Intelligence Platform…Anywhere. Powered by FDA-cleared ECG technology
BRINGING CARE BEYOND THE HOSPITAL A Cardiac Intelligence Platform…Anywhere. Powered by FDA-cleared ECG technology. HeartBeam is the first ever cable-free, synthesized, 12-Lead ECG platform, delivering clinical-grade insights in real time, wherever symptoms occur. Fourth Quarter 2025 Financial Result
Slide 5: HeartBeam System Cleared and Ready For Launch
HeartBeam System Cleared and Ready For Launch FDA 510(k) clearances for arrhythmia detection: 12/2024: The HeartBeam System 12/2025: 12-Lead ECG Synthesis Algorithm Strong IP: 25 Issued Patents Worldwide Robust Clinical Evidence: 14 Clinical Papers & Presentations Fourth Quarter 2025 Financial Resul
Slide 6: One platform. Two form factors. Shared cardiac intelligence.
CORE PLATFORM One platform. PATENTED 3D SIGNAL Two form factors. COLLECTION TECHNOLOGY Shared cardiac intelligence. FORM FACTORS ON–DEMAND HEATBEAM 12-LEAD PATCH SYSTEM CONTINUOUS CABLE-FREE 12-LEAD ECG 1-LEAD → 12-LEAD FOR AT-HOME USE ON DEMAND APPLICATIONS ENABLED ARRHYTHMIA HEART ATTACK PERSONALI
Slide 7: Major Strategic Initiatives for 2026
Major Strategic Initiatives for 2026 • Limited Commercial Launch of HeartBeam System • Complete Pilot Clinical Study to Support Heart Attack Detection Indication • Complete Development of 12-Lead ECG Patch, Drive Partnership Decision • Advance AI Development to Provide Unique Advantages Fourth Quart
Slide 8: Limited Commercial Launch
Limited Commercial Launch Fourth Quarter 2025 Financial Results Conference Call 8
Slide 9: An Ideal Early Market: Concierge and Preventive Cardiology
An Ideal Early Market: Concierge and Preventive Strong willingness to pay Evidence of demand Cardiology 1.5M+ Americans pay out of pocket for concierge medicine 80% 92% Cardiovascular care becomes a major healthcare spending category beginning in midlife (ages 45–70), a core HIGH-NET-WORTH HIGH-NET-
Slide 10: Focused Launch. Foundation for Scale.
Focused Launch. Foundation for Scale. Creates a Playbook to Accelerate Growth Nationwide Proving success in Cardiology and Executive Concierge Practices INITIAL MARKET ACCELERATING GROWTH: ENTRY POINT: NATIONAL CHAINS Concierge and Practice Size: 100,000-400,000 Preventive patients per network Cardi
Slide 11: Clear Plan to Fuel the Next Stage of Growth
Clear Plan to Fuel the Next Stage of Growth Apply what HeartBeam learns in a focused approach to accelerate efficient expansion 1ST HALF 2026 2ND HALF 2026 2027+ Validate premium value Prove deep adoption into Scale revenue proposition anchor accounts Move to a train-the-trainer Refine HeartBeam sys
Slide 12: Commercial Partnership with ClearCardio, a key part of launch strategy
HEARTBEAM INITIAL LAUNCH STRATEGY Commercial Partnership SIGN LEADING PRACTICES THAT WANT DEEP HEARTBEAM UTILIZATION with ClearCardio, a key part of launch strategy ClearCardio Exec Health Practice Exec Health Practice Partnering with leading cardiology and PARTNER CLOSELY TO DRIVE PATIENT ADOPTION
Slide 13: Heart Attack Detection
Heart Attack Detection Fourth Quarter 2025 Financial Results Conference Call 13
Slide 14: Heart Attack Detection
Heart Attack Detection Clinical-grade heart attack detection, available wherever patients are. 20M+ high-risk patients in the U.S. Problem Why We Win Patients can’t recognize a heart attack Two proof of concept studies show HeartBeam at home is similar to standard 12-Lead ECG 12-Lead ECG is only in
Slide 15: Heart Attack Detection: Clinical Validation Underway
Heart Attack Detection: Clinical Validation Underway We are rapidly advancing clinical validation to support indication expansion into acute ischemia / heart attack detection. ALIGN-ACS Pilot Study Initiated HEADSTART-ACS Study ALIGN-ACS Pilot Study Alignment with FDA on (Europe) Initiated (Indonesi
Slide 16: Unveiling the On-Demand 12-Lead Patch
Unveiling the On-Demand 12-Lead Patch Fourth Quarter 2025 Financial Results Conference Call 16
Slide 17: HeartBeam's On-Demand 12-Lead Patch: Disrupting the Patch Market
HeartBeam’s On-Demand 12-Lead Patch: Disrupting the Patch Market TODAY'S PATCH MARKET HEARTBEAM ON-DEMAND 12-LEAD PATCH Patch monitors are a $2B Development of Working Prototype of revenue market with Patch complete existing reimbursement Clinical grade 12-Lead ECG Devices are 1-3 leads, which limit
Slide 18: HeartBeam's 12-Lead Technology Fills Key Gaps, Draws Strong Physician Demand
HeartBeam’s 12-Lead Technology Fills Key Gaps, Draws Strong Physician Demand PHYSICIANS WANT TO SWITCH PHYSICIANS WILL PRESCRIBE MORE TO 12-LEAD PATCH (MARKET ACTUALLY GROWS) PHYSICIANS THAT CURRENTLY FOR USE CASES, WHERE MDs PRESCRIBE FOR USE CASES, WHERE MDs DO PRESCRIBE PATCH MONITORS OTHER CARDI
Slide 19: Fourth Quarter 2025 Financial Results Conference Call
Click here to watch the video Click here to watch the video 12L patch product not cleared by FDA and not available for sale in the United States or other geographies. Fourth Quarter 2025 Financial Results Conference Call
Slide 20: HeartBeam's AI Initiative
HeartBeam’s AI Initiative Fourth Quarter 2025 Financial Results Conference Call 20
Slide 21: HeartBeam AI Uniquely Brings 12-Lead Personalized Insights to Patients at Home
HeartBeam AI Uniquely Brings 12-Lead Personalized Insights to Patients at Home 12-Lead ECG AI exists today, but only in clinical settings. HeartBeam enables longitudinal 12-Lead insights at home. 12-Lead ECG + AI Today HeartBeam’s CLINICALLY PROVEN ACROSS: Differentiation DRIVERS: • • More personali
Slide 22: Mt. Sinai Partnership
Mt. Sinai Partnership HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home Accelerates development of personalized Positions HeartBeam to expand from cardiac AI algorithms on the HeartBeam symptom-based cardiac rhythm platform across we
Slide 23: 2026 Milestones
2026 Milestones Fourth Quarter 2025 Financial Results Conference Call 23
Slide 24: Upcoming Milestones
Upcoming Milestones Continued progress on commercialization and other major corporate initiatives Q1 26 Q2 26 Q3 26 Q4 26 2027- 12-LEAD FDA VALIDATE PREMIUM ESTABLISH FUNNEL FOR 2027 GOALS SCALE REVENUE CLEARANCE POSITIONING 12-LEAD LIMITED DEVELOP PROOF POINTS FOR ADOPTION LAUNCH SIGN/ONBOARD FURTH
Slide 25: Financials
Financials Fourth Quarter 2025 Financial Results Conference Call 25
Slide 26: Financial Discipline Aligned to Achieving Milestones
Financial Discipline Aligned to Achieving Milestones • Net cash used in operating activities of $14.0M in 2025, including just $2.9M in Q4 2025. YEAR-OVER-YEAR QUARTERLY CHANGE YEAR-OVER-YEAR ANNUAL CHANGE • 30% decrease compared to same Quarter Ended December 31, Year Ended December 31, quarter pri
Slide 27: Summary
Summary • 12-Lead ECG Synthesis FDA clearance was a major milestone • Commencing limited commercial launch • Initial commercial partnership with ClearCardio • Clear plan to launch and scale • Pilot clinical study for heart attack detection underway • 12-Lead patch has potential to disrupt a $2B mark
Slide 28: Company Investor Relations
Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050 MKT-110 v1 Fourth Quarter 2025 Financial